3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Glioblastoma
1
Genomic Instability
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Adenocarcinoma of Lung
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
ALK Gene Rearrangement Positive
1
Interventions
brigatinib
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
ALK+ Advanced NSCLC
×
alectinib
×
Clear all
NCT03596866
2025-09-12
ALTA-3
Takeda
Phase 3
Completed
248 enrolled
20 charts